J
James A. Hutchinson
Researcher at University Hospital Regensburg
Publications - 95
Citations - 3721
James A. Hutchinson is an academic researcher from University Hospital Regensburg. The author has contributed to research in topics: Transplantation & Immunosuppression. The author has an hindex of 31, co-authored 87 publications receiving 3241 citations. Previous affiliations of James A. Hutchinson include University of Regensburg & St George's Hospital.
Papers
More filters
Journal ArticleDOI
Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene.
TL;DR: 5 novel, single-nucleotide polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor (VEGF) gene are characterized and the frequency distribution of the polymorphic alleles in the population of healthy volunteers is described and the functional significance of the 18-n nucleotide insertion is investigated.
Journal ArticleDOI
Cutting Edge: Immunological Consequences and Trafficking of Human Regulatory Macrophages Administered to Renal Transplant Recipients
James A. Hutchinson,James A. Hutchinson,Paloma Riquelme,Paloma Riquelme,Birgit Sawitzki,Birgit Sawitzki,Stefan Tomiuk,Stefan Tomiuk,Patrick Miqueu,Maaz Zuhayra,Hans Heinrich Oberg,Andreas Pascher,Ulf Lützen,Uwe Janßen,Uwe Janßen,Christiane Broichhausen,Lutz Renders,Friedrich Thaiss,Ernst Scheuermann,Eberhard Henze,Hans-Dieter Volk,Hans-Dieter Volk,Lucienne Chatenoud,Robert I. Lechler,Robert I. Lechler,Kathryn J. Wood,Kathryn J. Wood,Dieter Kabelitz,Hans J. Schlitt,Edward K. Geissler,Edward K. Geissler,Fred Fändrich +31 more
TL;DR: Regulatory macrophages warrant further study as a potential immune-conditioning therapy for use in solid-organ transplantation, and are being used to inform the design of The ONE Study, a multinational clinical trial of immunomodulatory cell therapy in renal transplantation.
Journal ArticleDOI
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
Birgit Sawitzki,Paul N. Harden,Petra Reinke,Aurélie Moreau,James A. Hutchinson,David Game,Qizhi Tang,Eva C. Guinan,Manuela Battaglia,William J. Burlingham,Ian S.D. Roberts,Mathias Streitz,Régis Josien,Carsten A. Böger,Cristiano Scottà,James F. Markmann,Joanna Hester,Karsten Juerchott,Cécile Braudeau,Ben James,Ben James,Laura Contreras-Ruiz,Jeroen B. van der Net,Tobias Bergler,Rossana Caldara,William Petchey,Matthias Edinger,Matthias Edinger,Nathalie Dupas,Michael Kapinsky,Ingrid Mutzbauer,Ingrid Mutzbauer,Natalie M Otto,Robert Öllinger,Maria P. Hernandez-Fuentes,Fadi Issa,Norbert Ahrens,Christoph Meyenberg,Sandra Karitzky,Ulrich Kunzendorf,Stuart J. Knechtle,Josep M. Grinyó,Peter J. Morris,Peter J. Morris,Leslie Brent,A. Bushell,Laurence A. Turka,Jeffrey A. Bluestone,Robert I. Lechler,Hans J. Schlitt,M. C. Cuturi,Stephan Schlickeiser,P Friend,Tewfik Miloud,Alexander Scheffold,Antonio Secchi,Kerry Crisalli,Sang-Mo Kang,Rachel Hilton,Bernhard Banas,Gilles Blancho,Hans-Dieter Volk,Giovanna Lombardi,Kathryn J. Wood,Edward K. Geissler,Edward K. Geissler,Edward K. Geissler +66 more
TL;DR: In this paper, the authors evaluated the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment in kidney transplant patients and found that CBMP is achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infectious complications, but similar rejection rates in the first year.
Journal ArticleDOI
Differentiation of In Vitro–Modified Human Peripheral Blood Monocytes Into Hepatocyte–like and Pancreatic Islet-like Cells
Maren Ruhnke,Hendrik Ungefroren,Andreas K. Nussler,Franz Martín,Marc Brulport,Wiebke Schormann,Jan G. Hengstler,Wolfram Klapper,Karin Ulrichs,James A. Hutchinson,Bernat Soria,Reza Parwaresch,P. F. Heeckt,Bernd Kremer,Fred Fändrich +14 more
TL;DR: The ability to reprogram, expand, and differentiate peripheral blood monocytes in large quantities opens the real possibility of the clinical application of programmable cells of monocytic origin in tissue repair and organ regeneration.
Journal ArticleDOI
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study
Mathias Streitz,Tewfik Miloud,Michael Kapinsky,Michael R Reed,Robert T. Magari,Edward K. Geissler,James A. Hutchinson,Katrin Vogt,Stephan Schlickeiser,Anders Handrup Kverneland,Christian Meisel,Hans-Dieter Volk,Birgit Sawitzki +12 more
TL;DR: The ONE Study panel may be adopted as a standardized method for monitoring patients in clinical trials enrolling transplant patients, particularly trials of novel tolerance promoting therapies, to facilitate fair and meaningful comparisons between trials.